The following is a summary of the Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript:

Financial Performance:

• Aytu BioPharma achieved $5.1 million in adjusted EBITDA, up from the previous year's $0.7 million.

• A steady cash balance of $19.5 million was maintained, compared to $20 million in the September quarter.

• The company saw a 49% rise in ADHD portfolio revenues, reaching a record of $16.6 million.

• In Q2 2024, Aytu BioPharma reported revenues of $22.9 million, a 13% decrease compared to Q2 2023.

• The Rx segment, however, reported a 4% revenue increase, garnering $18.8 million, with the ADHD portfolio contributing significantly.

• Despite a dip in the Prescription Pediatric portfolio's net revenue by 66%, the company recorded its first quarterly operating profit of $2.4 million as a result of cost reduction and winding down the Consumer Health segment.

• The company, however, reported a $220,000 net loss after factoring in income tax expenses.

Business Progress:

• A strategic shift has been implemented to position Aytu as a specialty pharma company focusing on novel prescription therapeutics.

• Aytu BioPharma is set to conclude operations in its Consumer Health segment by June 2024.

• The company anticipates resurgent multivitamin revenues over the coming quarters, following issues with order timing caused by a payer change.

• Plans are in motion to outsource ADHD production as the company anticipates completing the divestment of the Consumer Health segment by the end of the fiscal year.

• Operational modifications and an expected recovery in Pediatric sales are forecasted to lay a robust foundation for a strong end to fiscal 2024 and a promising start to fiscal 2025.

More details: Aytu BioPharma IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.